RecruitingPhase 2NCT07257055
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Sponsor
M.D. Anderson Cancer Center
Enrollment
30 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Acalabrutinib, a drug called Glofitamab, and others for people with btki, glofitamab, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAcalabrutinib
Given by po
DRUGRituximab
Given by IV
DRUGGlofitamab
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07257055
Related Trials
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT0669718417 locations
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
NCT072837051 location
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
NCT072590701 location
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT0619288810 locations
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT074603621 location